Dupixent® (dupilumab) approved in the european union as the first-ever targeted therapy for patients with copd

First-in-world approval of dupixent for adults with uncontrolled copd with raised blood eosinophils based on two landmark phase 3 trials showing dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life
REGN Ratings Summary
REGN Quant Ranking